Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.5M | $8.16M | $1.13M | $18.0K | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $110M |
| Revenue growth | — | -53.5% | -86.2% | -98.4% | 65450.0% | 307.2% | 34.0% | 28.5% | 9.3% | 21.4% |
| Gross profit | $17.5M | $7.56M | -$675K | $18.0K | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | $97.3M |
| Gross margin | 99.8% | 92.6% | -59.8% | 100.0% | 91.4% | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating income | $798K | -$19.9M | -$77.2M | -$109M | -$127M | -$92.3M | -$79.0M | -$65.5M | -$96.8M | -$125M |
| Operating margin | 4.6% | -244.5% | -6842.2% | -608211.1% | -1074.2% | -192.1% | -122.8% | -79.2% | -107.1% | -113.7% |
| Net income | -$1.94M | -$20.0M | -$75.7M | -$105M | -$128M | -$111M | -$110M | -$102M | -$127M | -$153M |
| Net margin | -11.1% | -245.2% | -6707.2% | -584144.4% | -1088.9% | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
| EPS (diluted) | -$1.91 | -$2.14 | -$4.80 | -$5.12 | -$5.90 | -$4.96 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.19M | -$9.57M | -$37.3M | -$71.0M | -$106M | -$84.9M | -$87.6M | -$76.4M | -$96.8M | -$162M |
| Capital expenditures | $695K | $271K | $560K | $325K | $1.22M | $752K | $254K | $194K | $295K | $289K |
| Free cash flow | $3.49M | -$9.84M | -$37.9M | -$71.3M | -$107M | -$85.6M | -$87.8M | -$76.6M | -$97.1M | -$163M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.4M | $37.0M | $101M | $49.7M | $52.9M | $44.4M | $55.4M | $95.0M | $172M | $111M |
| Total assets | $23.1M | $75.5M | $104M | $202M | $122M | $120M | $136M | $178M | $286M | $200M |
| Total liabilities | $6.75M | $7.04M | $13.5M | $22.1M | $25.6M | $111M | $225M | $244M | $295M | $306M |
| Long-term debt | — | — | — | — | — | $0.00 | $97.5M | $98.6M | $122M | $122M |
| Shareholders' equity | $16.3M | $68.5M | $90.1M | $180M | $96.4M | $8.41M | -$89.4M | -$65.2M | -$8.80M | -$105M |
| Retained earnings | -$27.2M | -$47.2M | -$123M | -$228M | -$357M | -$467M | -$577M | -$679M | -$806M | -$960M |
| Shares (wtd avg diluted) | 2.31M | 13.8M | 16.2M | 21.0M | 22.2M | 22.3M | 22.8M | 28.8M | 42.9M | 48.1M |
Every figure is extracted from UroGen Pharma Ltd.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.